Compare LOPE & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOPE | ACAD |
|---|---|---|
| Founded | 1949 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.8B |
| IPO Year | 2008 | 2000 |
| Metric | LOPE | ACAD |
|---|---|---|
| Price | $152.00 | $21.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 22 |
| Target Price | ★ $220.00 | $30.55 |
| AVG Volume (30 Days) | 222.7K | ★ 1.2M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | ★ 2.80 | 0.02 |
| Revenue | $511,257,000.00 | ★ $726,437,000.00 |
| Revenue This Year | $8.67 | $18.80 |
| Revenue Next Year | $6.66 | $11.70 |
| P/E Ratio | ★ $53.82 | $1,062.50 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $145.00 | $19.69 |
| 52 Week High | $223.04 | $28.35 |
| Indicator | LOPE | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 42.68 | 49.76 |
| Support Level | $148.07 | $21.04 |
| Resistance Level | $155.20 | $22.03 |
| Average True Range (ATR) | 4.12 | 0.59 |
| MACD | 0.27 | 0.05 |
| Stochastic Oscillator | 55.26 | 57.35 |
Grand Canyon Education Inc is a publicly traded education services company dedicated to serving colleges and universities. GCE's university partner is Grand Canyon University, an Arizona non-profit corporation that operates a comprehensive regionally accredited university that offers graduate and undergraduate degree programs, emphases, and certificates across nine colleges, both online and on the ground at its campus in Phoenix, Arizona, and at four off-site classroom andlaboratory sites. The Company generates all of its revenue through service agreements with its university partners.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.